部份中文舍曲林处方资（仅供参考）
药品英文名
Sertraline
药品别名
盐酸舍曲林、郁乐复、左乐复、左洛复、Sertralin
药物剂型
片剂：50mg，100mg。
药理作用
舍曲林是选择性5-羟色胺再摄取抑制药(SSRI)。对5-羟色胺(5-HT)再摄取的抑制作用强化了5-HT受体神经传递。此外，舍曲林还抑制了缝际区5-羟色胺神经之放电，由此增强了蓝斑区的活动，形成了突触后膜β受体与突触前膜α2受体的低敏感化。舍曲林不与肾上腺素α1、α2或β受体结合，也与胆碱受体、γ-氨基丁酸(GABA)受体或苯二氮卓类受体无亲和作用。
药动学
口服吸收缓慢，4.5～8.5h可达血药峰值。在肝内进行广泛的首过代谢。血浆蛋白结合率为98%。主要通过脱甲基途径代谢，然后形成葡萄糖醛酸结合物。t1/2为24～26h。主要以代谢物分别随尿和粪便等量排出。
适应证
用于治疗抑郁症或预防其发作。国外已批准用于治疗强迫性障碍。
禁忌证
1.对本品高度敏感者禁用。
2.严重肝肾功能不全者禁用。
注意事项
1.慎用于有癫痫病史者、躁狂/轻症躁狂发作者、食欲或体重改变者、近期曾发生心肌梗死、心脏疾病者、肝功不全患者、血小板聚集功能受损患者、血容量不足或使用利尿药者，尤其在老年患者。
2.老年人、儿童、妊娠及哺乳期妇女使用安全性：未见老年人服药发生危害的报告。
儿童用药的安全性尚未建立。大鼠实验中按体重服用80mg/kg，相当于人类按体重服用剂量的20倍，可见生殖率下降。缺乏对人体妊娠的实验资料，对分娩与产程的影响尚不详。孕妇不宜使用。舍曲林能否自乳汁中分泌出尚不详。哺乳期妇女不宜使用。
3.药物过量与处理：
有证据表明，舍曲林在过量服用后仍有很大的安全范围。在曾有报告中，舍曲林单独过量服用高达8g。过量服用舍曲林后没有特别的解毒方法及解毒剂。应开放并保持呼吸道通畅，确保充分的给氧及通气。能与导泻剂合用的药用炭可考虑用于治疗用药过量，与催吐或洗胃同样或更为有效。在对症和支持疗法的同时，建议进行心脏及生命体征监测。
由于舍曲林在体内有广泛的分布容积，强迫利尿、透析、血液灌注及换血疗法均无明显意义。
4.肝病患者应用应慎重。由于舍曲林经肾脏排泄很少，肾功能不全者的给药剂量无需根据肾脏损害程度进行调整。
5.其他：用药前后或用药时应当检查或监测的项目有：
(1)疗效的指征：
抑郁症：
目标症状的改善(抑郁情绪、自杀倾向、口味改变、乏力、睡眠模式改变、在平常的活动中缺乏愉悦兴趣、过度的负罪感、无意义的感觉、精神运动性抑制或激动、思考或集中注意力或记忆困难)。
强制性障碍：
插入性和无意识的冲动、念头或思想的再发和持续减少或解除；减少或缓解对强迫性意念的重复和刻意的动作表演反应。
恐慌障碍：
减少或缓解伴随恐慌障碍的体征或症状(呼吸困难、心悸、战栗、出汗、瞬间发热或发冷、胸痛或不适、恐惧死亡或情感失控)。
(2)中毒的监测：通常早期发生锥体外系反应包括张力障碍反应、帕金森样运动失调及精神安定药恶性综合征，建议开始治疗的4周内，每周监测患者情况。胃肠道不良反应(恶心、呕吐)常发生于治疗初期，一般在2～3周后缓解。在治疗初期，还需密切监视患者的自杀倾向。治疗期内有可能发生乏力、反应迟钝或操作机敏度下降，驾驶车辆、操纵机器等应倍加小心。治疗期内不宜饮酒，亦不能使用其他中枢神经抑制药。在单胺氧化酶抑制药停药后2周内不可使用舍曲林。停用舍曲林2周后才可使用单胺氧化酶抑制药。建议患者在服用舍曲林期间避免摄入葡萄汁。甜橙汁可提供相同的基础营养，但不影响本品的代谢。
不良反应
常见有食欲或体重下降、性功能减低、头痛、头晕、多汗、失眠、腹泻、恶心、胃或腹部痉挛性疼痛、乏力、震颤等。少见的不良反应有焦虑、激动、不安、视物不清、便秘、皮肤潮红、心悸等。
用法用量
开始口服每天50mg，数周后可逐渐增至每天200mg。当剂量超过每天150mg时，连续用药时间不得超过8周。获得满意疗效后，剂量应减至最低有效量予以维持，一般为每天50mg。
药物相应作用
与单胺氧化酶抑制药(MAOI)合用，极易出现致命的高血压危象。可延长地西泮的t1/2。
专家点评
无镇静或兴奋作用，无抗胆碱或单胺氧化酶抑制作用，能改善顺应性作用。不良反应比三环类药物少。
HOW SUPPLIED
ZOLOFT (sertraline hydrochloride) capsular-shaped scored tablets, containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline, are packaged in bottles.
ZOLOFT 25 mg Tablets: light green film coated tablets engraved on one side with ZOLOFT and on the other side scored and engraved with 25 mg.
  NDC 0049-4960-30               Bottles of 30

  NDC 0049-4960-50               Bottles of 50
ZOLOFT 50 mg Tablets: light blue film coated tablets engraved on one side with ZOLOFT and on the other side scored and engraved with 50 mg.
  NDC 0049-4900-30               Bottles of 30
  NDC 0049-4900-66               Bottles of 100
  NDC 0049-4900-73               Bottles of 500
  NDC 0049-4900-94               Bottles of 5000
  NDC 0049-4900-41               Unit Dose Packages of 100
ZOLOFT 100 mg Tablets: light yellow film coated tablets engraved on one side with ZOLOFT and on the other side scored and engraved with 100 mg.
  NDC 0049-4910-30               Bottles of 30
  NDC 0049-4910-66               Bottles of 100
  NDC 0049-4910-73               Bottles of 500
  NDC 0049-4910-94               Bottles of 5000
  NDC 0049-4910-41               Unit Dose Packages of 100
Store at 25°C (77°F); excursions permitted to 15° – 30°C (59° – 86°F)[see USP Controlled Room Temperature].
ZOLOFT Oral Concentrate: ZOLOFT Oral Concentrate is a clear, colorless solution with a menthol scent containing sertraline hydrochloride equivalent to 20 mg of sertraline per mL and 12% alcohol. It is supplied as a 60 mL bottle with an accompanying calibrated dropper.
  NDC 0049-4940-23               Bottles of 60mL
Store at 25°C (77°F); excursions permitted to 15° – 30°C (59° – 86°F) [see USP Controlled Room Temperature].
----------------------------------------------
Zoloft (sertraline HCl)
Company: Pfizer
Approval Status: Approved May 2002
Treatment for: Mood disorders
Areas: Pregnancy & Gynecology; Psychiatry/Psychiatric
Possible similar drugs: Zoloft; Zoloft
General Information
Zoloft has been approved for the treatment of Premenstrual Dysphoric Mood Disorder (PMDD). It can be taken either daily or for the two weeks before a woman's period. Zoloft is also indicated for the treatment of depression, posttraumatic stress disorder, panic disorder and obsessive-compulsive disorder.
PMDD exhibits symptoms similar to those seen with major depressive disorder and other mood disorders, but is distinguishable from such disorders by its cyclical nature. The intense physical and emotion symptoms associated with PMDD are present only between ovulation and menstruation. It is estimated that three to five percent of American women suffer from PMDD.
Clinical Results
The approval of Zoloft for the treatment of PMDD is supported by two placebo-controlled trials involving 532 women diagnosed with the disorder. Zoloft was significantly more effective in improving emotional and behavioral symptoms of PMDD than placebo, regardless if the drug was taken continously or only during the premenstrual phase of the menstrual cycle. These symptoms included feelings of being depressed, hopeless or overwhelmed, and being angry or irritable and having conflicts with others. Those who were admistered Zoloft every day also noted improvement in physical symptoms including breast tenderness, bloating and headache.
https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=20730